Suppr超能文献

兔重复使用倍他米松:治疗差异对肾上腺抑制、肺成熟和妊娠结局的影响。

Repeated use of betamethasone in rabbits: effects of treatment variation on adrenal suppression, pulmonary maturation, and pregnancy outcome.

作者信息

Pratt L, Magness R R, Phernetton T, Hendricks S K, Abbott D H, Bird I M

机构信息

Perinatal Research Labs and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Wisconsin-Madison, Wisconsin, USA.

出版信息

Am J Obstet Gynecol. 1999 Apr;180(4):995-1005. doi: 10.1016/s0002-9378(99)70672-1.

Abstract

OBJECTIVE

The aim of the study was to determine whether reduced birth weight, adrenal suppression, and lung maturation occur in parallel and are cumulative with increasing courses of betamethasone.

STUDY DESIGN

Time-bred rabbits were assigned to a control group or to receive saline solution or 1, 2, or 3 courses of betamethasone (early treatment, beginning day 19). Two additional groups (n = 5 per group) were given 1 or 2 late courses (late treatment). Birth weight, serum cortisol, adrenal 17alpha-hydroxylase (P450c17) messenger ribonucleic acid and fetal lung surfactant proteins A and B were quantified on day 27.

RESULTS

Fetal weight was inversely proportional to the number of courses, with late treatment having a greater effect. Maternal cortisol and P450c17 levels were progressively suppressed with each early course, but fetal cortisol and P450c17 levels were only suppressed after 3 courses. A single late treatment profoundly suppressed both maternal and fetal cortisol and P450c17 messenger ribonucleic acid levels. In contrast, fetal lung surfactant proteins A and B increased progressively with betamethasone courses, regardless of timing.

CONCLUSIONS

Time from last injection to delivery determined adrenal suppression, whereas total betamethasone courses determined surfactant protein production. Lower birth weight was dependent on the number of courses and was greater with late treatment.

摘要

目的

本研究旨在确定出生体重降低、肾上腺抑制和肺成熟是否同时发生,以及随着倍他米松疗程的增加是否会累积出现。

研究设计

将定时配种的兔子分为对照组,或给予生理盐水,或接受1、2或3个疗程的倍他米松(早期治疗,从第19天开始)。另外两组(每组n = 5)给予1或2个晚期疗程(晚期治疗)。在第27天对出生体重、血清皮质醇、肾上腺17α-羟化酶(P450c17)信使核糖核酸以及胎儿肺表面活性物质蛋白A和B进行定量分析。

结果

胎儿体重与疗程数成反比,晚期治疗的影响更大。每个早期疗程都会使母体皮质醇和P450c17水平逐渐受到抑制,但胎儿皮质醇和P450c17水平仅在3个疗程后才受到抑制。单次晚期治疗会显著抑制母体和胎儿的皮质醇以及P450c17信使核糖核酸水平。相比之下,无论给药时间如何,胎儿肺表面活性物质蛋白A和B会随着倍他米松疗程的增加而逐渐增加。

结论

从最后一次注射到分娩的时间决定了肾上腺抑制情况,而倍他米松的总疗程数决定了表面活性物质蛋白的产生。较低的出生体重取决于疗程数,晚期治疗时出生体重更低。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验